Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Viatris Inc. Common Stock

VTRS

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Last trade $20.56
Day change -$0.185 (-0.89%)
Day range $20.41 – $20.92
Volume 3,287,650
Market cap $23.78B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$23.78B
Price / earnings
—
Price / book
1.74×
Price / sales
1.61×
EV / sales
2.4×
EV / EBITDA
12.09×

Profitability

Earnings per share
-$0.53
Return on assets
-1.75%
Return on equity
-4.44%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.97×
Current ratio
1.55×
Quick ratio
0.97×
Cash ratio
0.27×

Cash flow

Price / cash flow
9.57×
Price / free cash flow
11.27×
Free cash flow
$2.11B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VTRS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.75B$3.76B$3.52B$3.7B$3.76B$3.58B$3.25B$3.53B
Cost of revenue$2.31B$2.3B$2.36B$2.56B$2.39B$2.25B$2.09B$2.31B
Gross profit$1.44B$1.46B$1.16B$1.15B$1.37B$1.33B$1.16B$1.22B
Selling, general and administrative$950.8M$1.13B$928.8M$1.03B$886.6M$928.7M$948.1M$1.05B
Research and development$231.7M$242.5M$248.6M$323M$250.4M$218.8M$222M$234.8M
Total operating expenses$1.18B$1.45B$1.24B$1.34B$1.19B$1.1B$4.04B$1.39B
Operating income$261.5M$6.3M-$79.7M-$192.7M$178.8M$233M-$2.88B-$179.8M
Interest expense-$112.4M-$120.7M-$120.1M-$119.6M-$119.6M-$116.6M-$115.5M-$120.2M
Income before taxes$127.9M-$64M-$247.3M-$343M-$7.9M-$217.1M-$3.1B-$526.5M
Income taxes$453.2M$54.8M-$423.7M-$2.9M$120.3M-$212.5M-$55M-$10M
Net income-$325.3M-$118.8M$176.4M-$340.1M-$128.2M-$4.6M-$3.04B-$516.5M
Net income attributable to common shareholders-$325.3M-$118.8M$176.4M-$340.1M-$128.2M-$4.6M-$3.04B-$516.5M
EBITDA$947.7M$751.8M$649.9M$571M$923M$863.7M$645.8M$678M
Basic earnings per share-$0.28-$0.10$0.15-$0.29-$0.11$0.00-$2.55-$0.43
Diluted earnings per share-$0.28-$0.10$0.15-$0.29-$0.11$0.00-$2.55-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

VTRS or DHR: Which Is the Better Value Stock Right Now?

A comparison of two Medical Services stocks reveals that Viatris (VTRS) presents a better value opportunity than Danaher (DHR). VTRS has a Zacks Rank of #2 (Buy) with improving earnings outlook and superior valuation metrics, including a forward P/E of 7.98 versus DHR's 27.39, and a Value grade of A compared to DHR's C.

GlobeNewswire Inc.

Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

Opus Genetics announced completion of dosing in Cohort 2 of its OPGx-BEST1 Phase 1/2 trial with data expected in Q1 2027. The company also reported full enrollment of its OPGx-LCA5 Phase 3 registrational trial with dosing to begin in Q4 2026, FDA clearance for OPGx-RDH12, and FDA approval of phentolamine ophthalmic solution for presbyopia. With $89 million in cash, the company projects runway into 2029.

Zacks Investment Research

Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 Earnings

Viatris reported Q3 2026 revenue of $3.75 billion, down 0.3% year-over-year and slightly missing consensus estimates by 0.76%. However, the company delivered a strong EPS beat of 10.94%, reporting $0.71 versus the expected $0.64. Regional performance was mixed, with Greater China showing strong growth of 14.2%, while Emerging Markets Generics declined sharply by 36.5%. The stock has outperformed the broader market with a 9.9% return over the past month and currently holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y

Viatris (VTRS) beat Q3 adjusted EPS expectations at 71 cents versus 64 cents consensus, driven by margin expansion and strong Greater China sales growth of 14.2%. However, total revenues of $3.75 billion missed estimates and declined 0.3% year-over-year due to supply disruptions in Europe and Emerging Markets. The company raised full-year 2026 adjusted EPS guidance to $2.56-$2.63, though manufacturing suspension at its Nashik facility threatens Q4 revenues with an estimated $100 million impact.

Zacks Investment Research

Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.12 per share
Declared
Nov 2, 2026
Ex-dividend
Nov 23, 2026
Pay date
Dec 16, 2026
Ex-dividendAmount / sharePay dateType
Aug 21, 2026$0.12Sep 16, 2026recurring
May 22, 2026$0.12Jun 17, 2026recurring
Mar 9, 2026$0.12Mar 18, 2026recurring
Nov 24, 2025$0.12Dec 15, 2025recurring
Aug 22, 2025$0.12Sep 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.